公开(公告)号：US20170051306A1

公开(公告)日：2017-02-23

申请号：US15111084

申请日：2015-01-14

Applicant: KAGOSHIMA UNIVERSITY

Inventor： Ken-ichiro Kosai ,  Kaoru Mitsui ,  Kanako Ide

IPC: C12N15/86 ,  C12Q1/68

CPC classification number: C12N15/86 ,  A61K48/00 ,  C07K2319/92 ,  C12N2740/15043 ,  C12N2830/008 ,  C12Q1/6897 ,  G01N33/5011 ,  G01N33/5073

Abstract: The invention provides a method to search for a best promoter for reliably targeting a cancerization-causing cell in human ES/iPS cells. Discovering a gene which can kill or remove a cancerization-causing cell contained in human ES/iPS cells with high efficiency is also provided. A method is provided for removing an undifferentiated cell, which remains after the differentiation of human ES/iPS cells into desired cells, with high efficiency and comprehensively. A viral vector is provided which includes a nucleotide sequence and a recombination cassette. The nucleotide sequence contains a target gene and a killing gene that are linked to each other through a sequence that enables the simultaneous expression of the two genes by one promoter. The recombination cassette contains a promoter region which is so linked as to enable the expression of the labeling gene and the killing gene. The viral vector may contain a promoter specific to an undifferentiated cell.

Abstract translation: 本发明提供了一种搜索用于可靠地靶向人ES / iPS细胞中的致癌细胞的最佳启动子的方法。 还提供了能够以高效率杀死或除去人ES / iPS细胞中所含致癌细胞的基因的基因。 提供了一种用于去除未分化细胞的方法，该细胞在人ES / iPS细胞分化成所需细胞后保持高效率和全面。 提供了包含核苷酸序列和重组盒的病毒载体。 核苷酸序列包含通过能够通过一个启动子同时表达两个基因的序列彼此连接的靶基因和杀死基因。 重组盒含有如此连接的启动子区，以使得能够表达标记基因和杀死基因。 病毒载体可以含有对未分化细胞特异性的启动子。

公开(公告)号：US12297268B2

公开(公告)日：2025-05-13

申请号：US18363113

申请日：2023-08-01

Applicant: Kyowa Kirin Co., Ltd. ,  KAGOSHIMA UNIVERSITY

Inventor： Nobuaki Takahashi ,  Ryosuke Nakano ,  Sayaka Maeda ,  Yuji Ito

IPC: C07K16/28 ,  A61K47/10 ,  A61K47/36 ,  C12N5/12 ,  G01N33/563

Abstract: The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.

公开(公告)号：US20240391950A1

公开(公告)日：2024-11-28

申请号：US18035914

申请日：2021-10-22

Applicant: Kagoshima University

Inventor： Yuji ITO ,  Hiroshi NAKAYAMA ,  Md Abdur RAFIQUE

IPC: C07K1/107 ,  A61K47/64 ,  C07K14/00

Abstract: A crosslinking agent for a protein or a peptide is represented by the following formula (I). In the formula, A is a hydrogen atom, a C1 to 6 alkyl group optionally substituted with a phenyl group or a halogen atom, or a phenyl group.

公开(公告)号：US20240359152A1

公开(公告)日：2024-10-31

申请号：US18569175

申请日：2022-06-10

Applicant: Kagoshima University

Inventor： Takayuki TAKEI ,  Masahiro YOSHIDA ,  Yoshihiro OHZUNO

IPC: B01J13/16 ,  B01J2/02

CPC classification number: B01J13/16 ,  B01J2/02

Abstract: A tubular body (111) has a shape of tube surrounding a virtual center line (VL). A guide groove (112) that is helical about the virtual center line (VL) is provided in the inner surface of the tubular body (111). A rotation device (120) rotates the tubular body (111) around the virtual center line (VL). A dropping device (130) drops, on the inner surface of the tubular body (111), an inclusion substance and a wall material precursor liquid that is a precursor of a wall material covering the inclusion substance. A liquid droplet dropped by the dropping device (130) rolls in the guide groove (112) of the tubular body (111), the tubular body (111) being rotated by the rotation device (120).

公开(公告)号：US20240301171A1

公开(公告)日：2024-09-12

申请号：US18274389

申请日：2022-01-27

Applicant: KAGOSHIMA UNIVERSITY ,  Tokuyama Corporation

Inventor： Masahiro YOSHIDA ,  Takayuki TAKEI ,  Yoshihiro OHZUNO ,  Kengo NISHIO ,  Yasutomo SHIMIZU ,  Kazuishi FUKUDA ,  Takayoshi KAWASAKI

IPC: C08K7/22 ,  B01J13/16 ,  B24B37/24

CPC classification number: C08K7/22 ,  B01J13/16 ,  B24B37/24 ,  C08K2201/003

Abstract: The fine hollow particle of the present invention is a fine hollow particle composed of a resin film comprising a melamine-based resin, in which the resin film is composed of a plurality of small piece-shaped portions and a bonding portion for bonding the plurality of small piece-shaped portions. According to the present invention, it is possible to provide stable fine hollow particles having excellent solvent resistance and heat resistance, good dispersibility, and a large particle diameter.

公开(公告)号：US20240148807A1

公开(公告)日：2024-05-09

申请号：US18406002

申请日：2024-01-05

Applicant: Kagoshima University

Inventor： Ken-ichiro KOSAI ,  Nobuhiro Ijichi

IPC: A61K35/761 ,  A61P35/04 ,  C12N15/86 ,  C12N15/861

CPC classification number: A61K35/761 ,  A61P35/04 ,  C12N15/86 ,  C12N15/861

Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.

公开(公告)号：US20230181587A1

公开(公告)日：2023-06-15

申请号：US17997974

申请日：2021-05-07

Applicant: KAGOSHIMA UNIVERSITY ,  OSAKA UNIVERSITY

Inventor： Takashi KURIHARA ,  Ichiro TAKASAKI ,  Hitoshi HASHIMOTO ,  Atsuko HAYATA ,  Yusuke SHINTANI

IPC: A61K31/519 ,  A61K31/4178 ,  A61P25/24 ,  A61P25/22

CPC classification number: A61K31/519 ,  A61K31/4178 ,  A61P25/24 ,  A61P25/22

Abstract: This invention relates to an antidepressant/anxiolytic drug comprising a compound represented by the following formula (I) or (II),




wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group;

or a salt thereof, or a solvate thereof.

公开(公告)号：US11583463B2

公开(公告)日：2023-02-21

申请号：US16642818

申请日：2018-08-31

Applicant: Kagoshima University ,  Marumae Co., Ltd.

Inventor： Yong Yu ,  Takashi Morimoto ,  Toshikazu Maeda ,  Koei Igarashi

IPC: A61H1/02

Abstract: A hemiplegic forearm function recovery training device includes a forearm mounting part (2) on which a forearm (S) is to be mounted. The forearm mounting part (2) includes a mounting body (20), an inner frame portion (2B), an outer frame portion (2A), and a control part. The mounting body (20) has a forearm fixing portion (22) on which the forearm (S) is mounted and a gripping mechanism (23) capable of being gripped by a hand of the forearm (S). The inner frame portion (2B) is fitted to the mounting body (20) and is rotatable around the forearm (S). The outer frame portion (2A) guides the inner frame portion (2B) in a rotation direction thereof. The control part performs a series of controls that repeatedly causes normal rotation, stop, reverse rotation, and stop of the inner frame portion (2B) while acquiring rotation angle information of the inner frame portion (2B). In the normal rotation the control part controls angular velocity or acceleration of the inner frame portion (2B) to stimulate a training target muscle of the forearm (S) and in the reverse rotation the control part provides resistance to the inner frame portion (2B) to sustain stimulation to the training target muscle to maintain muscle tone.

公开(公告)号：US20220363716A1

公开(公告)日：2022-11-17

申请号：US17770978

申请日：2020-10-23

Applicant: Kagoshima University

Inventor： Yuji Ito ,  Nobuaki Takahashi ,  Ryosuke Nakano ,  Sayaka Maeda

IPC: C07K1/22 ,  C07K16/12 ,  C07K7/08 ,  A61K47/64 ,  C07K16/32

Abstract: An objective is to provide an Fc-modified antibody or the like having a long serum half-life according to a CCAP method, more specifically, an antibody or the like where IgBP is bound to only one site, based on findings of the inventors. Provided is an objective antibody or the like by purification and production of an Fc-modified antibody or the like with a column bound to an Fc region of an antibody. Specifically, an antibody where only one of two binding sites of Fc is selectively modified is provided by allowing an IgBP-bound antibody produced by a CCAP method to adsorb to a carrier of an IgBP-immobilized column, or forming a state where only one Fc of an antibody is bound to an IgBP binding column and then adding a peptide reagent for CCAP to the column to perform a reaction of a CCAP method in the column.

公开(公告)号：US11472865B2

公开(公告)日：2022-10-18

申请号：US16620715

申请日：2018-05-18

Applicant: Kagoshima University

Inventor： Yuji Ito

IPC: C07K16/00 ,  C07K14/00

Abstract: It is an object of the present invention to provide a method for modifying an antibody in a specific and simple manner, and others. The present invention relates to: an IgG-binding peptide, an IgG-binding peptide modified with a crosslinking agent, a complex of an IgG-binding peptide modified with the crosslinking agent and IgG, a method for producing the complex, and others.